top of page

Pleryon Therapeutics Joints JLABS@Shanghai

2021年8月9日

Pleryon Therapeutics is pleased to announce its residency at Johnson & Johnson Innovation JLABS@Shanghai.


Yu Yu, founder and CEO of Pleryon, stated, “We are grateful to the Johnson & Johnson Innovation Global Selection Committee for recognizing the Pleryon team, technology, and strategic direction. We will leverage Johnson & Johnson Innovation’s global network and resources to accelerate the advancement of our independent research and development pipeline in ophthalmology and other indications. We look forward to collaborating with JLABS members and peers in the pharmaceutical industry.”


JLABS is an open innovation ecosystem connected to a global network, enabling innovators to bring life-saving and quality-of-life-improving health solutions to patients worldwide more quickly. As a leader in the field of innovation, JLABS is open to entrepreneurs in the pharmaceutical, medical device, consumer, and health technology industries, helping them provide healthcare solutions to patients and consumers. JLABS@Shanghai is the largest in Johnson & Johnson’s global network and the first JLABS in Asia. For more information, please visit http://jlabs.jnjinnovation.com/.


Pleryon Therapeutics is a biotech company committed to becoming an innovative leader in biofunctional polymers and drug carriers, addressing unmet clinical needs and improving people’s living standards through world-leading polymer technology. For more information, please visit http://www.pleryon.com/.

bottom of page